Relmada Therapeutics (RLMD) EBITDA Margin (2012 - 2013)
Relmada Therapeutics (RLMD) posted quarterly EBITDA Margin of 776.97% for Q4 2013, down 35724.0% year-over-year from N/an in Q4 2012, and up 74.72% quarter-over-quarter from 3073.34% in Q2 2013.
Powered by 
Analysis
Relmada Therapeutics (RLMD) EBITDA Margin (2012 - 2013) Analysis & Trends
Relmada Therapeutics (RLMD) has reported EBITDA Margin for 2 consecutive years, with 776.97% the latest figure, recorded in Q4 2013.
- In Q4 2013, EBITDA Margin fell 35724.0% year-over-year to 776.97%; the TTM figure through Nov 2013 stood at 786.85% (changed N/A YoY), while the FY2013 annual figure was 877.66%, down 72589.0% from the prior year.
- EBITDA Margin grew to 776.97% in Q4 2013 per RLMD's latest filing, from 3073.34% in the prior quarter.
- Across five years, EBITDA Margin topped out at 176.73% in Q1 2013 and bottomed at 3073.34% in Q2 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Nov 30, 2013 | -776.97% |
| May 31, 2013 | -3,073.34% |
| Feb 28, 2013 | -176.73% |
| Nov 30, 2012 | -419.73% |
| Aug 31, 2012 | -569.57% |
| May 31, 2012 | -620.25% |